EXHIBIT 11
COMPUTATION OF EARNINGS PER COMMON SHARE ("EPS")
OMNICARE, INC. AND SUBSIDIARY COMPANIES
UNAUDITED
(in thousands, except per share data)
Three Months Ended
March 31,
-------------------
2004 2003
-------- --------
Basic Earnings:
Net income $ 63,491 $ 40,423
======== ========
Shares
Weighted average number of common shares outstanding 103,458 94,386
======== ========
Basic EPS $ 0.61 $ 0.43
======== ========
Diluted Earnings (a)(b):
Net income $ 63,491 $ 40,423
Interest expense related to 5.0% Convertible Debentures,
net of taxes -- 2,922
-------- --------
Net income, as adjusted, for purposes of calculating
diluted EPS $ 63,491 $ 43,345
======== ========
Shares
Weighted average number of common shares outstanding 103,458 94,386
Additional shares assuming conversion of:
Stock options and stock warrants (c) 1,311 931
5.0% Convertible Debentures -- 8,712
-------- --------
Weighted average common shares outstanding, as adjusted 104,769 104,029
======== ========
Diluted EPS $ 0.61 $ 0.42
======== ========
(a) The three month period ended March 31, 2003 includes the dilutive effect of
the $345.0 million of 5.0% convertible subordinated debentures ("5.0%
Convertible Debentures"), which assumes conversion using the "if converted"
method. Under that method, the 5.0% Convertible Debentures are assumed to
be converted to common shares (weighted for the number of days assumed to
be outstanding during the period) and interest expense, net of taxes,
related to the 5.0% Convertible Debentures is added back to net income. In
July 2003, the Company completed the early redemption of the entire $345.0
million aggregate principal amount of the outstanding 5.0% Convertible
Debentures.
(b) The $345.0 million of 4.0% convertible trust preferred securities due 2033,
which are convertible at a fixed conversion price of $40.82 (under a
contingent conversion feature whereby the holders may convert their trust
PIERS if the closing sales price of Omnicare common stock for a
predetermined period, beginning with the quarter ending September 30, 2003,
is more than 130% of the then-applicable conversion price or, during a
predetermined period, if the daily average of the trading prices for the
trust PIERS is less than 105% of the average of the conversion values for
the trust PIERS through 2028, 98% for any period thereafter through
maturity), were outstanding during the three months ended March 31, 2004,
but were not included in the computation of diluted EPS because the impact
was anti-dilutive.
(c) During the three months ended March 31, 2004 and 2003, the anti-dilutive
effect associated with selected options and warrants was excluded from the
computation of diluted earnings per share, since the exercise price of
these options and warrants was greater than the average market price of the
Company's common stock during these periods. The aggregate anti-dilutive
stock options and warrants excluded for the quarter ended March 31, 2004
and 2003 totaled 2.0 million and 5.1 million, respectively.